KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q1 2025 value amounting to $7.7 million.

  • Supernus Pharmaceuticals' Gains from Investment Securities rose 19416.28% to $7.7 million in Q1 2025 from the same period last year, while for Sep 2025 it was $20.6 million, marking a year-over-year increase of 20340.71%. This contributed to the annual value of $53.3 million for FY2024, which is 4549.48% up from last year.
  • According to the latest figures from Q1 2025, Supernus Pharmaceuticals' Gains from Investment Securities is $7.7 million, which was up 19416.28% from $12.9 million recorded in Q4 2024.
  • Over the past 5 years, Supernus Pharmaceuticals' Gains from Investment Securities peaked at $12.9 million during Q4 2024, and registered a low of -$8.8 million during Q2 2021.
  • Its 5-year average for Gains from Investment Securities is $1.6 million, with a median of $743000.0 in 2022.
  • In the last 5 years, Supernus Pharmaceuticals' Gains from Investment Securities surged by 197848.1% in 2022 and then crashed by 65126.58% in 2024.
  • Quarter analysis of 5 years shows Supernus Pharmaceuticals' Gains from Investment Securities stood at $79000.0 in 2021, then surged by 1978.48% to $1.6 million in 2022, then skyrocketed by 481.43% to $9.5 million in 2023, then soared by 35.24% to $12.9 million in 2024, then crashed by 40.67% to $7.7 million in 2025.
  • Its Gains from Investment Securities stands at $7.7 million for Q1 2025, versus $12.9 million for Q4 2024 and -$1.0 million for Q3 2024.